IBS (Irritable Bowel Syndrome)

Cannabis has gained attention as a potential treatment for Irritable Bowel Syndrome (IBS), a gastrointestinal disorder characterized by symptoms like abdominal pain, bloating, diarrhea, and constipation. Cannabinoids, particularly cannabidiol (CBD) and tetrahydrocannabinol (THC), have been shown to influence the endocannabinoid system, which plays a key role in regulating gastrointestinal motility, pain perception, and inflammation (Storr et al., 2002). These compounds may offer relief by modulating the digestive system's function and alleviating pain and discomfort associated with IBS (Izzo & Camilleri, 2009).

CBD, known for its anti-inflammatory and analgesic properties, may reduce gut inflammation, which is believed to contribute to IBS symptoms (Schicho et al., 2009). THC, on the other hand, has been shown to help manage the pain and discomfort associated with IBS and reduce the frequency of spasms (Lutz, 2009). Furthermore, cannabis may help regulate bowel movements, as it has been linked to improved motility in both diarrhea and constipation-dominant forms of IBS (Cichewicz, 2004).

While cannabis shows promise as an adjunctive treatment, more research is needed to determine the ideal dosages, delivery methods, and long-term safety of cannabinoids for IBS patients.

References

1. Storr, M., & Sibaev, A. (2002). The role of cannabinoids in gastrointestinal motility. Current Opinion in Pharmacology, 2(6), 719-725.
2. Izzo, A. A., & Camilleri, M. (2009). Cannabinoids in gastrointestinal and liver diseases. The Journal of Clinical Gastroenterology, 43(4), 223-234.
3. Schicho, R., et al. (2009). Cannabinoid receptors as therapeutic targets in gastrointestinal diseases. Pharmacology & Therapeutics, 123(1), 54-61.
4. Lutz, B. (2009). The endocannabinoid system and its relevance for the treatment of gastrointestinal diseases. British Journal of Pharmacology, 158(3), 907-922.
5. Cichewicz, R. H. (2004). The role of cannabinoids in the regulation of gastrointestinal motility. Biochemical Pharmacology, 68(1), 1-11.